Compare Cassava Sciences Inc (FLNA) vs Toyota Motor Corp (TM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Toyota Motor Corp — how do they compare? Cassava Sciences Inc trades at $1.06 (market cap $53.14M), while Toyota Motor Corp trades at $179.75 (market cap $210.48B). The key difference: Toyota Motor Corp is far larger — about 3960.9× Cassava Sciences Inc's market cap, and Toyota Motor Corp pays a 3.54% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | TM | |
|---|---|---|
Market Cap | $53.14M | $210.48B |
Sector | Health | Consumer Cyclical |
52-Week High | $4.64 | $248.29 |
52-Week Low | $1.09 | $166.50 |
Enterprise Value | -$33.43M | $374.67B |
Dividend Yield | — | 3.54% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.
Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.
Toyota Motor (TM) trades at $179.34, up 1.77% today, with a neutral technical signal and bullish moving averages. The stock shows strong fundamentals with a P/E of 9.69 and consistent earnings beats, including Q1 2026 EPS of $4.00 versus $3.11 expected. Recent news highlights a $3.6 billion Texas plant expansion to shift Tacoma production from Mexico, signaling growth commitment.
TM presents a value opportunity with attractive valuation ratios and solid profitability, but faces risks from competitive pressures and fluctuating net income margins. Analyst consensus is mixed with 37.5% buy ratings, indicating cautious optimism. The stock's outlook hinges on successful execution of US manufacturing investments and hybrid vehicle demand amid economic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Toyota Motor Corp
Founded in 1937, Toyota is one of the world's largest automakers with 10.38 million units sold at retail in fiscal 2022 across its light vehicle brands. Brands include Toyota, Lexus, Daihatsu, and truck maker Hino.
Read more on TM →
